Posted by Michael Wonder on 20 Dec 2022
Atara Biotherapeutics’ Ebvallo (tabelecleucel) receives European Commission approval as first ever therapy for adults and children with EBV+ PTLD
19 December 2022 - Pierre Fabre to lead commercialisation and distribution activities in Europe.
Atara Biotherapeutics and Pierre Fabre today announced that the European Commission has granted marketing authorisation for Ebvallo (tabelecleucel) as a monotherapy for the treatment of adult and paediatric patients two years of age and older with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.
